6-氟-3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚 | 180161-14-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 6-氟-3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚
• 英文名称: 6-fluoro-3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole
• 英文别名: 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine；6-Fluoro-3-[1,2,3,6-tetrahydro-pyridin-4-yl]-1H-indole；6-Fluoro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole；4-(6-fluoroindol-3-yl)-1,2,5,6-tetrahydropyridine；3-(1,2,3,6-tetrahydro-4-pyridinyl)-6-fluoro-1H-indole；6-Fluoro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole
• CAS: 180161-14-2
• 化学式: C₁₃H₁₃FN₂
• mdl: MFCD04114772
• 分子量: 216.258
• InChiKey: FBWKDFSEFVFKFY-UHFFFAOYSA-N

物化性质

• 沸点：
  403.6±45.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  6-氟-3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 6-氟-3-(哌啶-4-基)-1H-吲哚
  参考文献：
  名称：

  新型组胺H1拮抗剂：吲哚基哌啶基苯甲酸衍生物的合成与构效关系。

  摘要：

  制备了一系列的吲哚基哌啶基衍生物，并对其作为组胺H（1）拮抗剂的活性进行了评估。结构-活性关系研究旨在提高我们的第一个前导分子的体内活性和药代动力学特征（1）。吲哚环上位置6上的氟取代在抑制组胺诱导的皮肤血管通透性测定中导致较高的体内活性，但对5HT（2）受体的选择性较低。在该系列中进行了广泛的优化，并鉴定了许多组胺H（1）拮抗剂，这些拮抗剂在体内具有强大的作用力和作用时间长，脑渗透力低或具有心脏毒性的潜力。在这个新系列中，吲哚基哌啶15、20、48、51和52在大鼠中显示出长的半衰期，并已被选择用于进一步的临床前评估。

  DOI：

  10.1021/jm0498203
• 作为产物：
  描述：

  2-乙炔基-5-氟苯胺 在 copper(l) iodide 、 磷酸 、 溶剂黄146 、 calcium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 6-氟-3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚
  参考文献：
  名称：

  3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as High Affinity, Selective, and Orally Bioavailable h5-HT_2A Receptor Antagonists

  摘要：

  The development of very high affinity, selective, and bioavailable h5-HT2A receptor antagonists is described. By investigation of the optimal position for the basic nitrogen in a series of 2-phenyl-3-piperidylindoles, it was found that with the basic nitrogen at the S-position of the piperidine it was not necessary to further substitute the piperidine in order to obtain good binding at h5-HT2A receptors. This meant the compounds no longer had high affinity at the IKr potassium channel, an issue with previous series of 2-aryl-3-(4-piperidyl)indoles. Improvements could be made to oral bioavailability in this series by reduction of the pK(a) of the basic nitrogen, by adding a fluorine atom to the piperidine ring, leading to 3-(4-fluoropiperidin-3-yl)-2-phenyl-1H-indole (17). Metabolic studies with this compound identified oxidation at the B-position of the indole as a major route in vitro and in vivo in rats. Blocking this position with a fluorine atom led to 6-fluoro-3-(4-fluoropiperidin-3-yl)-2-phenyl-1H-indole (22), an antagonist with 0.06 nM affinity for h5-HT2A receptors, with bioavailability of 80% and half-life of 12 h in rats.

  DOI：

  10.1021/jm0004998

文献信息

• Compounds having effects on serotonin-related systems
  申请人：Eli Lilly and Company

  公开号：US05741789A1

  公开（公告）日：1998-04-21

  A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

  一系列的杂氧烷胺类化合物是治疗与血清素再摄取和血清素1A受体有关或受其影响的疾病的有效药物。这些化合物特别适用于缓解尼古丁和烟草戒断症状，以及治疗抑郁症和其他需要使用血清素再摄取抑制剂的疾病。
• Novel selective and potent 5-HT reuptake inhibitors with 5-HT1D antagonist activity: chemistry and pharmacological evaluation of a series of thienopyran derivatives
  作者：Alicia Torrado、Carlos Lamas、Javier Agejas、Alma Jiménez、Nuria Dı́az、Jeremy Gilmore、John Boot、Jeremy Findlay、Lorna Hayhurst、Louise Wallace、Richard Broadmore、Rosemarie Tomlinson

  DOI：10.1016/j.bmc.2004.07.059

  日期：2004.10

  combining the naphthylpiperazine and thienopyran scaffolds has been prepared and evaluated for 5-HT reuptake inhibition with 5-HT1D antagonist activity. The design of these compounds has been based on the 'overlapping type' strategy where two pharmacophores are linked in a single molecule. The resultant dual pharmacological profile has the potential to deliver a more efficient treatment for depression

  已经制备了一系列结合萘基哌嗪和噻吩并吡喃骨架的化合物，并评估了具有5-HT1D拮抗剂活性的5-HT再摄取抑制作用。这些化合物的设计基于“重叠类型”策略，其中两个药效团连接在一个分子中。所得的双重药理学特征具有提供更有效的抑郁症治疗的潜力。
• Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
  申请人：Wyeth

  公开号：US20030236241A1

  公开（公告）日：2003-12-25

  Compounds of the formula 1 useful for the treatment of depression and other conditions such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, sexual dysfunction, eating disorders, addictive disorders caused by ethanol or cocaine abuse and related illnesses.

  该式化合物用于治疗抑郁症和其他疾病，如强迫症、恐慌发作、广泛性焦虑障碍、性功能障碍、进食障碍、由乙醇或可卡因滥用引起的成瘾障碍及相关疾病。
• 1H-2,1,3-benzothiadiazine-2,2-dioxide compounds or derivatives thereof
  申请人：Eli Lilly and Company Limited

  公开号：US05929072A1

  公开（公告）日：1999-07-27

  A pharmaceutical compound having the formula: ##STR1## in which n is 1 or 2, m is 1 or 2, p is 1 to 6, q is 0 or 1 to 3, R.sup.1 and R.sup.2 are each hydrogen or C.sub.1-4 alkyl, R.sup.3, R.sup.4 and R.sup.5 are each hydrogen, C.sub.1-4 alkyl, optionally substituted phenyl or optionally substituted phenyl-C.sub.1-4 alkyl, or R.sup.3 and R.sup.4 together form an alkylene link of formula --(CH.sub.2).sub.3 -- or --(CH.sub.2).sub.4 --, or R.sup.4 and R.sup.5 together with the carbon atom to which they are attached form a C.sub.3-6 cycloalkyl group, R.sup.6 is C.sub.1-4 alkyl, C.sub.1-4 alkoxy, carboxy, hydroxy, cyano, halo, trifluoromethyl, nitro or amino, the dotted line represents an optional double bond, and the fluorine atom is attached at the 6 or 7-position; and salts and esters thereof.

  一种具有以下结构式的药物化合物：##STR1## 其中n为1或2，m为1或2，p为1至6，q为0或1至3，R.sup.1和R.sup.2分别为氢或C.sub.1-4烷基，R.sup.3、R.sup.4和R.sup.5分别为氢、C.sub.1-4烷基、可选择取代的苯基或可选择取代的苯基-C.sub.1-4烷基，或者R.sup.3和R.sup.4一起形成一个结构式为--(CH.sub.2).sub.3--或--(CH.sub.2).sub.4--的烷基链，或者R.sup.4和R.sup.5与它们连接的碳原子一起形成一个C.sub.3-6环烷基基团，R.sup.6为C.sub.1-4烷基、C.sub.1-4烷氧基、羧基、羟基、氰基、卤素、三氟甲基、硝基或氨基，虚线代表可选的双键，氟原子连接在第6或第7位；以及其盐和酯。
• Benzothiadiazinyl-indole derivatives and their use as serotonin receptor ligands
  申请人：ELI LILLY AND COMPANY LIMITED

  公开号：EP0897921A1

  公开（公告）日：1999-02-24

  Compounds having the formula: in which n is 1 or 2, m is 1 or 2, p is 1 to 6, q is 0 or 1 to 3, R1 and R2 are each hydrogen or C1-4 alkyl, R3, R4 and R5 are each hydrogen, C1-4 alkyl, optionally substituted phenyl or optionally substituted phenyl-C1-4 alkyl, or R3 and R4 together form an alkylene link of formula -(CH2)3- or -(CH2)4-, or R4 and R5 together with the carbon atom to which they are attached form a C3-6 cycloalkyl group, R6 is C1-4 alkyl, C1-4 alkoxy, carboxy, hydroxy, cyano, halo, trifluoromethyl, nitro or amino, the dotted line represents an optional double bond, and the fluorine atom is attached at the 6 or 7-position; and salts and esters thereof, are binding to the 5-HT serotonin receptor and are useful in the treatment of CNS disorders.

  具有以下化学式的化合物： 其中n为1或2，m为1或2， p为1至6，q为0或1至3， R1和R2分别为氢或C1-4烷基， R3、R4和R5分别为氢、C1-4烷基、可选择取代的苯基或可选择取代的苯基-C1-4烷基，或者R3和R4一起形成化学式-(CH2)3-或-( )4-的烷基链，或者R4和R5与它们连接的碳原子一起形成C3-6环烷基团， R6为C1-4烷基、C1-4烷氧基、羧基、羟基、氰基、卤素、三氟甲基、硝基或氨基， 虚线表示可选的双键，和 氟原子连接在6位或7位； 以及它们的盐和酯，与5-HT血清素受体结合，并在中枢神经系统疾病的治疗中有用。